SUMMARY

[0011] The invention and its various embodiments are set out in the claims that form part of this patent application. In one aspect, the present disclosure refers to the use of an orally-administered effective dose of L-4-chlorokynurenine in the manufacture of a medicament for treating tinnitus.

[0011a] In another aspect, the present disclosure refers to the use of an orally-administered effective dose of L-4-chlorokynurenine in the manufacture of a medicament for treating obsessive-compulsive disorder.

[0012] Without limiting the foregoing, in one example, the disclosure relates to pharmaceutical compositions that per unit dose consist essentially of L-4-chlorokynurenine in an amount of about 360, 1,080 or 1,440 mg, together with pharmaceutically acceptable ingredients such as carriers and excipients. Another example involves the administration of therapeutically effective amounts of these compounds to treat conditions, disorders and diseases described in this specification, preferably certain conditions, disorders and diseases caused by neurological dysfunction.

[0013] Another example relates to dosing protocols for the compositions described herein, such as the administration of a daily dose of from about 1 to about 14 or from about 1 to about 30 days, more preferably from about 7 to about 24 days, and most preferably from about 12 to about 16 days.

[0014] Another example described herein relates to compositions and methods for the treatment of depression and for the treatment of various types of pain, including hyperalgesia, by administering a therapeutically effective amount of L-4-chlorokynurenine. Other examples include the treatment of anxiety, thoughts of hopelessness, self-harm or suicide and/or an absence of positive thoughts or plans, major depressive disorder (MDD), dysthymic disorder (or dysthymia), persistent depressive disorders, atypical depression, bipolar depression or manic depression, seasonal affective disorder (SAD), psychotic depression and postpartum depression, psychotic depression, premenstrual syndrome, premenstrual dysphoric disorder, anxiety, mood disorder, depressions caused by chronic medical conditions such as cancer or chronic pain, chemotherapy, chronic stress, post-traumatic stress disorders, risk of suicide. Such therapies optionally include the co-administration of L-4-chlorokynurenine along with another antidepressant or mood elevating therapy including cognitive and psychotherapy.

[0015] In another example, the disclosure relates to pharmaceutical compositions and associated therapeutic methods of administering L-4-chlorokynurenine in an amount that produces plasma

CLAIMS

1. Use of an orally-administered effective dose of L-4-chlorokynurenine in the manufacture of a medicament for treating tinnitus.

2. The use of claim 1, wherein the effective dose of L-4-chlorokynurenine is an amount from 50 mg to 1,800 mg per day or is an amount of 360, 1,080 or 1,440 mg per day; and wherein the L-4-chlorokynurenine is optionally to be administered together with a pharmaceutically acceptable carrier or excipient.

3. Use of an orally-administered effective dose of L-4-chlorokynurenine in the manufacture of a medicament for treating obsessive-compulsive disorder.

4. The use of claim 3, wherein the effective dose of L-4-chlorokynurenine is an amount from 50 mg to 1,800 mg per day or is an amount of 360, 1,080 or 1,440 mg per day; and wherein the L-4-chlorokynurenine is optionally to be administered together with a pharmaceutically acceptable carrier or excipient.